International Journal of STD & AIDS > Volume 20, Number 6 > Pp. 425-426

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Google Scholar Articles by Mallewa, J E Articles by Vilar, F J PubMed PubMed Citation Social Bookmarking                      What's this?

Audit reports

Cardiovascular disease risk management in HIV patients, experiences from Greater Manchester

J E Mallewa MRCP , S P Higgins FRCP, S Garbett, N Saxena MBBS and F J Vilar MRCP MD

Departments of Infectious Diseases, Genito-Urinary Medicine and Audit, North Manchester General Hospital, Crumpsall, Manchester M8 5RB, UK

Correspondence to: Dr J E Mallewa, Department of Sexual Health, Trafford General Hospital, Davyhulme, Manchester M41 5SL, UK Email: janemallewa{at}yahoo.com

Antiretroviral (ARV) therapy in HIV patients can cause hyperlipidaemia, glucose intolerance and insulin resistance, which increase the risk of cardiovascular disease (CVD). An audit carried out in Manchester found that CVD risk factors were common among HIV patients receiving ARVs; however, the management of risk factors was not satisfactory. Adopting a formal system to identify and manage CVD risk factors as well as appropriate referral for specialist management of complications of ARV therapy would improve patient care.

Key Words: HIV • cardiovascular disease • antiretroviral therapy

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?